Our drug development pipeline currently includes four active programs in clinical or preclinical development stages. All of our drug candidates are small molecules designed for oral delivery.
Vyvanse™ (lisdexamfetamine dimesylate, formerly NRP104) is under FDA review for the treatment of ADHD in pediatric populations.
We are developing NRP290 to treat acute pain as an alternative to Lortab®, Vicodin® and Vicoprofen®. NRP290 is intended to be a safer, abuse-resistant and effective alternative to currently marketed opioids. NRP409 is being developed as a replacement or supplemental therapy in patients with primary hypothyroidism and other indications.
NRP369 has been repositioned as a backup to NRP290.
This website contains certain trademarks, trade names and
service marks of other companies, including Concerta®,
Cylert®, Demerol®, Endocet®, Lortab®, OxyContin®,
Percodan®, Percocet®, Ritalin®, Strattera®,
Vicodin® and Vicoprofen®, which are the property of
their respective owners.